Shannon Westin

Trials

Studies that name Shannon Westin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:25 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05715216 · EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

  M.D. Anderson Cancer Center · active not recruiting · Ovarian Cancer · principal investigator
• Ph1
  NCT05636111 · Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

  M.D. Anderson Cancer Center · recruiting · Ovarian Cancer · principal investigator
• Early Ph1
  NCT05053750 · TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  M.D. Anderson Cancer Center · active not recruiting · Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer · principal investigator
• Ph2
  NCT03579316 · Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  M.D. Anderson Cancer Center · active not recruiting · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma · principal investigator
• Ph1
  NCT03162627 · Selumetinib and Olaparib in Solid Tumors

  M.D. Anderson Cancer Center · active not recruiting · Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs · principal investigator
• Ph1
  NCT02433626 · Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

  Critical Outcome Technologies Inc. · unknown · Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer · principal investigator
• Early Ph1
  NCT02316834 · Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  M.D. Anderson Cancer Center · completed · Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass · principal investigator
• N/A
  NCT02093546 · Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290

  M.D. Anderson Cancer Center · completed · Recurrent Endometrial Carcinoma · principal investigator
• Ph1
  NCT01591356 · EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

  M.D. Anderson Cancer Center · active not recruiting · Advanced Malignant Solid Neoplasm · principal investigator
• Ph1
  NCT01187199 · Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

  M.D. Anderson Cancer Center · active not recruiting · Advanced Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Paul Calabresi Clinical Oncology Award
  K12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $476,200 awarded in 2026
  Same name and institution; not confirmed by an ID
• Protocol Review and Monitoring System
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $344,069 awarded in 2026
  Grant number is on one of their registry trials
• Targeting p300 to Overcome PARP inhibitor resistance induced by acidic tumor microenvironment
  P50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 · $341,501 awarded in 2023
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
  P50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ROBERT C BAST · fiscal years 1999 to 2015
  Named on NCT02316834
• The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
  P50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ELIZABETH A GRIMM · fiscal years 2004 to 2014
  Named on NCT01591356